Webinars

The liver is crucial for metabolizing foreign substances, and drug-induced liver damage is a significant cause for the removal of drugs from the market. Traditional 2D models of human liver cells rapidly lose their viability and functionality within 1-2 weeks, limiting the feasibility of long-term drug exposure studies. In this webinar, Dr. Darren Heywood will introduce Promega's 3D cell-based assays and how a multi-assay approach can help generate more biologically relevant data. Dr. Jonathan Sheard and Dr. Johanna Lampe, from UPM Biomedicals, will expand on this by describing their 3D cell-based assay multiplexing strategy for monitoring the long-term health and functionality of a HepaRG 3D Liver model cultured in GrowDex® over a four-week time course.

The rising demand for cell therapies and therapeutic antibodies calls for innovative development technologies. A major challenge is the analysis of antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis (ADCP), critical for therapeutic antibodies' effectiveness. Join our featured speakers, Julia Gilden from Promega and David Coberta Lopez from Charles River, as they highlight technological advances and share Charles River’s experiences with innovative bioassays. Discover how these solutions advance the development of cell therapies and therapeutic antibodies, making the discovery and manufacture of novel drugs more efficient and effective.